

## Novel pooling strategy with sample concentration for screening of SARS-CoV-2


Reverse transcription PCR (RT-PCR) is the gold standard for rapidly confirming infection with SARS-CoV-2. However, the great demand for SARS-CoV-2 RT-PCR testing has outpaced its supply in some scenarios, such as the large-scale testing of asymptomatic subjects for public health interventions. Notably, sample pooling, that is, combining multiple samples before and after nucleic acid extraction into a single test sample, has the potential to improve the available RT-PCR testing capacity.<sup>1 2</sup> However, compromised sensitivity caused by the sample dilution effect can lead to higher rates of false-negative results in low-viral-load specimens, which carries a risk of missing asymptomatic carriers capable of transmitting the infection.<sup>3-5</sup> Thus, developing a high-throughput testing strategy with no sensitivity loss for the early detection and active monitoring of individuals potentially exposed to SARS-CoV-2 is urgently required for prevention and control of the COVID-19 pandemic. Joung *et al* has demonstrated that increasing sample input via capturing all of the viral RNA from a nasopharyngeal swab (NPS) can boost the sensitivity of SARS-CoV-2 RT-PCR.<sup>6</sup> In this study, we compared the effectiveness and sensitivity of the traditional sample pooling (TSP) strategy and the sample pooling concentration (SPC) strategy for COVID-19 diagnosis using the automated

nucleic acid extraction system based on magnetic nanoparticles.


NPS in chemically inactivated buffer (Liferiver, Shanghai, China) obtained from patients with confirmed COVID-19 and health professionals were used for pooling. For each pool, 300  $\mu$ L of NPS from three samples and 200  $\mu$ L of NPS from eight samples were pooled into a single tube and mixed thoroughly. Two pooling strategies were evaluated as follows: (1) TSP strategy: part of the pooled samples, that is, 300  $\mu$ L of the three-TSP pool and 200  $\mu$ L of the eight-TSP pool, was subjected to RNA extraction using the Liferiver EX3600 and Autrax192 automatic nucleic acid extraction system (Liferiver); (2) SPC strategy: all pooled samples, that is, 900  $\mu$ L of the three-SPC pool and 1600  $\mu$ L of the eight-SPC pool, were subjected to RNA extraction using the Liferiver EX3600 and Autrax192 automatic nucleic acid extraction system (figure 1). In addition, individual analyses of the same samples were performed in parallel to the analysis of the pools. All RNA was eluted in 75  $\mu$ L elution buffer. A 10  $\mu$ L aliquot of RNA was used in 30  $\mu$ L of reaction using a real-time fluorescent RT-PCR kit targeting the SARS-CoV-2 ORF1ab gene (BGI, Shenzhen, China) on an Applied Biosystem 7500 Real Time PCR system (Thermo Fisher Scientific).<sup>7</sup> A sample was defined as positive if viral RNA was detected at threshold cycle (Ct) values of  $\leq 38$ , as indeterminate at Ct values of  $>38$  but  $<40$ , or as negative at Ct values of  $\geq 40$ , in accordance with the BGI kit instructions.

In total, we tested 21 three-sample and eight-sample pools for TSP and SPC (18 pools that each included at least 1 positive sample, composed of 54 and 144 individual samples; and 3 pools of all negative samples, composed of 9 and 24 individual samples) and also tested each sample individually in parallel. Of the 18 positive pools, 12 contained a single positive sample; 3 contained two positive samples; and 3 contained three positive samples (figure 2). All the pools containing only negative samples were confirmed as being negative, demonstrating 100% specificity (figure 2). For the positive TSP pools, 16/18 (88.9%) three-TSP and 17/18 (94.4%) eight-TSP were correctly detected (figure 2A). The four samples that were missed in the TSP pools each had a Ct value of  $\geq 36$ . Additionally, two three-TSP and eight-TSP pools containing one or two low-positive samples (Ct  $>34.6$ ) yielded indeterminate results, which indicated the need for pool retesting (figure 2). However, all 36 positive SPC pools, even those containing samples with low viral loads (Ct  $>36$ ), were correctly detected.

An important consideration in sample pooling is retaining sufficient sensitivity. Theoretically, pooling three and eight samples in the TSP strategy should increase the Ct value of a single positive sample by 1.58 and 3 cycles, respectively, but this should not happen in the SPC strategy owing to sample concentration. Of the pools that contained only one positive sample, the sample dilution inherent in the TSP strategy resulted in an average loss of 1.67 (95% CI 1.39 to 1.96) Ct for the three-TSP and 2.43 (95% CI 2.15 to



**Figure 1** Schematic overview of SARS-CoV-2 RT-PCR testing applying the TSP strategy or SPC strategy. Three or eight individual nasopharyngeal samples were pooled into a single sample. RNA was extracted from the pooled sample using the TSP and the SPC strategies. The extracted RNA was transferred to a PCR plate and subjected to RT-PCR targeting the SARS-CoV-2 ORF1ab gene. RT-PCR, reverse transcription PCR; SPC, sample pooling concentration; TSP, traditional sample pooling.



**Figure 2** Changes in Ct values for individual sample testing compared with the TSP strategy and SPC strategy. A total of 21 pools (pools 1–12 each contained one positive sample; pools 13–15 each contained two positive samples; pools 16–18 each contained three positive samples; and pools 19–21 each contained all negative samples), to which the TSP strategy or the SPC strategy was applied, were tested in parallel with the corresponding individual samples. (A) Three-sample pooling. (B) Eight-sample pooling. Ct, threshold cycle; SPC, sample pooling concentration; TSP, traditional sample pooling.

2.71) Ct for the eight-TSP when compared with individual sample tests (online supplemental table S1). In contrast, only slight Ct value losses were observed when using the SPC strategy, with an average change of 0.11 (95% CI –0.19 to 0.40) Ct in the three-SPC and 0.27 (95% CI 0.04 to 0.50) Ct in the eight-SPC (online supplemental table S1). In accordance with the theoretical estimation of Ct change, the empirical average change in Ct value was significantly different between the TSP and SPC strategies ( $p < 0.001$ , t-test). Furthermore, each of the pools that contained  $\geq 2$  positive samples showed Ct value change trends in the TSP and SPC strategies similar to those of pools containing only one positive sample when compared with individual sample tests.

Sample pooling is a major alternative strategy for large-scale SARS-CoV-2

screening in low-prevalence populations. Here, our data show that the sample dilution from traditional pooling (TSP strategy) led to a mild, but expected, loss in Ct value, in agreement with other studies.<sup>3–5</sup> This drop in sensitivity was responsible for all of the false-negative results in samples with low viral loads. However, use of the SPC strategy can effectively avoid sample dilution and yielded 100% accuracy with no loss of sensitivity, meaning that it may be possible to correctly identify all symptomatic and asymptomatic individuals with COVID-19. Unlike those of previous studies, in our approach, we did not need to consider the size of the pool for maximum efficiency based on COVID-19 prevalence,<sup>3 5 8</sup> only the capacity of the RNA extraction system in the laboratory where pooling was performed. Therefore, the SPC method as a resource-efficient

strategy may facilitate early detection and elimination of COVID-19 community transmission.

Xueliang Wang,<sup>1,2</sup> Zhongqiang Huang,<sup>1</sup> Jian Song,<sup>1</sup> Ran Zhao,<sup>2</sup> Yanqun Xiao,<sup>1</sup> Hualiang Wang<sup>1</sup>

<sup>1</sup>Department of Molecular Biology, Shanghai Center for Clinical Laboratory, Shanghai, China

<sup>2</sup>Department of Quality Control Material R&D, Shanghai Center for Clinical Laboratory, Shanghai, China

**Correspondence to** Dr Hualiang Wang and Dr Xueliang Wang, Department of Molecular Biology, Shanghai Center for Clinical Laboratory, Shanghai 200126, China; wanghualiang@sccl.org.cn, xlwang12@126.com

**Handling editor** Tahir S Pillay.

**Contributors** XW: concept, design, analysis and manuscript writing; ZH: concept, design and testing; JS: concept, design, testing and analysis; RZ: design and testing; YX: concept, design and analysis; and HW: concept, design, analysis, editing and supervision. All authors gave their final approval for this version of the article to be published.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Ethics approval** This study was approved by the ethics committee of the Shanghai Centre for Clinical Laboratory (202001). There were no risks to the participants. All data are reported anonymously and are managed confidentially.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jclinpath-2021-207579>).



**To cite** Wang X, Huang Z, Song J, et al. *J Clin Pathol* Epub ahead of print: [please include Day Month Year]. doi:10.1136/jclinpath-2021-207579

Received 27 March 2021  
Accepted 4 November 2021

*J Clin Pathol* 2021;**0**:1–3.  
doi:10.1136/jclinpath-2021-207579

#### ORCID iD

Hualiang Wang <http://orcid.org/0000-0002-4959-3287>

#### REFERENCES

- Hogan CA, Sahoo MK, Pinsky BA. Sample pooling as a strategy to detect community transmission of SARS-CoV-2. *JAMA* 2020;323:1967–9.
- Freire-Paspuel B, Vega-Mariño P, Velez A, *et al.* "Sample pooling of RNA extracts to speed up SARS-CoV-2 diagnosis using CDC FDA EUA RT-qPCR kit". *Virus Res* 2020;290:198173.
- Barak N, Ben-Ami R, Sido T, *et al.* Lessons from applied large-scale pooling of 133,816 SARS-CoV-2 RT-PCR tests. *Sci Transl Med* 2021;13. doi:10.1126/scitranslmed.abf2823. [Epub ahead of print: 14 Apr 2021].
- de Salazar A, Aguilera A, Trastoy R, *et al.* Sample pooling for SARS-CoV-2 RT-PCR screening. *Clin Microbiol Infect* 2020;26:1687.e1–1687.e5.
- Mitchell SL, Ventura SE. Evaluation and comparison of the Hologic Aptima SARS-CoV-2 assay and the CDC 2019-nCoV real-time reverse transcription-PCR diagnostic panel using a Four-Sample pooling approach. *J Clin Microbiol* 2020;58. doi:10.1128/JCM.02241-20. [Epub ahead of print: 18 Nov 2020].
- Joung J, Ladha A, Saito M, *et al.* Detection of SARS-CoV-2 with Sherlock one-pot testing. *N Engl J Med* 2020;383:1492–4.
- Wang X, Yao H, Xu X, *et al.* Limits of detection of 6 Approved RT-PCR kits for the novel SARS-Coronavirus-2 (SARS-CoV-2). *Clin Chem* 2020;66:977–9.
- Kevadiya BD, Machhi J, Herskovitz J, *et al.* Diagnostics for SARS-CoV-2 infections. *Nat Mater* 2021;20:593–605.

Table S1. Comparison of Ct values for individual positive samples compared to traditional sample pooling (TSP) strategy and sample pooling concentration (SPC) strategy<sup>a</sup>

Pool <sup>b</sup>	3-sample pooling					8-sample pooling				
	Individual Ct	TSP Ct	$\Delta$ Ct <sup>c</sup>	SPC Ct	$\Delta$ Ct <sup>c</sup>	Individual Ct	TSP Ct	$\Delta$ Ct <sup>c</sup>	SPC Ct	$\Delta$ Ct <sup>c</sup>
1	27.56	29.17	1.18	27.99	0.43	28.55	31.23	2.68	29.05	0.50
2	29.06	30.27	1.21	28.27	-0.79	29.50	32.32	2.82	29.99	0.49
3	28.31	30.53	2.22	28.38	0.07	29.67	32.16	2.49	30.04	0.37
4	28.66	29.98	1.32	27.95	-0.71	29.52	31.52	2.00	29.29	-0.23
5	28.62	30.01	1.39	28.84	0.22	28.85	31.32	2.47	29.34	0.49
6	33.33	35.09	1.76	33.65	0.32	29.51	31.57	2.06	29.24	-0.27
7	33.29	35.14	1.85	33.72	0.43	33.21	35.34	2.13	33.87	0.66
8	34.26	36.36	2.10	34.24	-0.02	33.39	35.28	1.89	33.72	0.33
9	34.86	36.16	1.30	35.49	0.63	34.67	37.41	2.74	35.07	0.40
10	36.68	38.04	1.36	37.01	0.33	34.66	36.54	1.88	35.37	0.71
11	36.22	38.03	1.81	36.79	0.57	36.38	39.17	2.79	36.07	-0.31
12	37.44	<b>40.00</b>	2.56	37.24	-0.20	36.76	<b>40.00</b>	3.24	36.87	0.11
13	27.99	28.99	N/A	27.72	N/A	28.55	30.50	N/A	27.89	N/A
	28.66					28.85				
14	33.33	34.16	N/A	32.63	N/A	29.67	32.19	N/A	30.03	N/A
	34.26					37.41				
15	36.68	<b>40.00</b>	N/A	37.51	N/A	33.21	35.57	N/A	33.25	N/A
	37.44					36.76				
16	29.06	29.41	N/A	27.99	N/A	29.50	30.94	N/A	29.03	N/A
	28.66					29.52				
	33.33					33.21				

17	33.29	34.38	N/A	33.09	N/A	33.39	36.61	N/A	34.27	N/A
	34.26					34.67				
	37.44					36.76				
18	36.68	37.43	N/A	36.36	N/A	36.38	38.08	N/A	35.54	N/A
	36.22					36.76				
	37.44					34.67				

<sup>a</sup>Ct: cycle threshold; Boldface type indicates samples that were missed when pooled; N/A: not applicable.

<sup>b</sup>pools 1-12 containing one positive sample, pools 13-15 containing two positive samples, pools 16-18 containing three positive samples.

<sup>c</sup>Values represent the difference between Ct values of the pooled group and corresponding individual positive sample.